Background: Ventricular tachycardia (VT) typically arises in patients with impaired left ventricular ejection fraction (LVEF). However, VT may also occur in individuals with preserved EF, highlighting the importance of myocardial fibrosis as an arrhythmogenic substrate. Cardiac m...
Open access
Research Article10.9734/ajcr/2025/v8i1315
Background: Hypertension is the most prevalent modifiable cardiovascular risk factor worldwide and a major driver of morbidity and mortality. In Morocco, prevalence is high and control rates remain suboptimal. Limited data exist applying the 2018 ESC–ESH cardiovascular risk (CVR)...
Open access
Research Article10.9734/ajcr/2025/v8i1311
Pulmonary arterial hypertension (PAH) is a rare but recognized adverse effect of tyrosine kinase inhibitors, notably Dasatinib, prescribed in chronic myeloid leukemia (CML). Due to potential reversibility, prompt recognition and management are essential. We report a 60-year-old m...
Open access
Research Article10.9734/ca/2025/v14i3497
Introduction: Papillary fibroelastoma is a rare benign cardiac tumor, usually discovered incidentally or during evaluation for embolic events. Its echocardiographic appearance often mimics infective endocarditis, making diagnosis challenging. Case Presentation: We report the case...
Open access
Research Article10.9734/ca/2025/v14i4502
Background: Right-sided infective endocarditis (RSIE) is typically associated with intravenous drug use or indwelling catheters. Its diagnosis in non-IV drug users is often delayed due to low clinical suspicion. The disease is often under-recognized in patients with atypical risk...
Open access
Research Article10.9734/ca/2025/v14i3496
Background: Fabry disease is a rare X-linked lysosomal storage disorder caused by mutations in the GLA gene, resulting in deficient activity of α-galactosidase A and subsequent accumulation of globotriaosylceramide (Gb3) in multiple organs. Cardiac involvement may mimic hypertrop...
Open access
Research Article10.9734/ajcr/2025/v8i1326
Background: Hypertension (HTN) is the leading modifiable risk factor for heart failure (HF) worldwide, particularly in low- and middle-income countries where blood pressure control remains suboptimal. Despite extensive international evidence, local data from Sub-Saharan Africa, i...
Open access
Research Article10.9734/ajcr/2025/v8i1324